J Biol Chem, Vol. 274, Issue 27, 18851-18856, July 2, 1999

Mutagenesis Identifies New Signals for -Amyloid Precursor Protein Endocytosis, Turnover, and the Generation of Secreted Fragments, Including A42^*

Ruth G. Perez^§, Salvador Soriano^¶, Jay D. Hayes, Beth Ostaszewski, Weiming Xia, Dennis J. Selkoe, Xiaohua Chen^¶, Gorazd B. Stokin^¶, and Edward H. Koo^¶

From the  Departments of Psychiatry and Neurobiology & Anatomy, Allegheny University of the Health Sciences, Pittsburgh, Pennsylvania 15212, the  Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115, and the ^¶ Department of Neurosciences, University of California, San Diego, La Jolla, California 92093

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

It has long been assumed that the C-terminal motif, NPXY, is the internalization signal for -amyloid precursor protein (APP) and that the NPXY tyrosine (Tyr⁷⁴³ by APP751 numbering, Tyr⁶⁸² in APP695) is required for APP endocytosis. To evaluate this tenet and to identify the specific amino acids subserving APP endocytosis, we mutated all tyrosines in the APP cytoplasmic domain and amino acids within the sequence GYENPTY (amino acids 737-743). Stable cell lines expressing these mutations were assessed for APP endocytosis, secretion, and turnover. Normal APP endocytosis was observed for cells expressing Y709A, G737A, and Y743A mutations. However, Y738A, N740A, and P741A or the double mutation of Y738A/P741A significantly impaired APP internalization to a level similar to that observed for cells lacking nearly the entire APP cytoplasmic domain (C), arguing that the dominant signal for APP endocytosis is the tetrapeptide YENP. Although not an APP internalization signal, Tyr⁷⁴³ regulates rapid APP turnover because half-life increased by 50% with the Y743A mutation alone. Secretion of the APP-derived proteolytic fragment, A, was tightly correlated with APP internalization, such that A secretion was unchanged for cells having normal APP endocytosis but significantly decreased for endocytosis-deficient cell lines. Remarkably, secretion of the A42 isoform was also reduced in parallel with endocytosis from internalization-deficient cell lines, suggesting an important role for APP endocytosis in the secretion of this highly pathogenic A species.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

APP¹ is a transmembrane protein with homology to glycosylated cell surface receptors (1), can reside at the cell surface (2-4) and is reinternalized via clathrin-coated pits (5, 6) to the endosomal-lysosmal pathway (7, 8). Some internalized APP remains intact to be recycled to the cell surface plasma membrane (9, 10). However, internalized APP can also be proteolytically processed into several distinct secreted fragments, which include the large secreted N-terminal APP ectodomain (APP_s), and A, the major protein component of senile plaques in Alzheimer's disease (AD; reviewed in Ref. 11).

Because A deposition may be central to AD pathogenesis, the mechanism by which A is generated from the precursor is an important focus of AD research. At least two species of A, differing by two amino acids at the C terminus (A40 and A42), are released from cells during normal cellular metabolism (12-14). A42, which readily aggregates in vitro (reviewed in Ref. 15) appears to be more pathogenic and may serve as a seed for plaque formation in individuals with AD (16), hereditary cerebral hemorrhage with amyloidosis Dutch type (17), and Down's syndrome (18). The source of A deposited in brain tissues is still uncertain. However, cell lines expressing wild type APP can produce and release A primarily after internalization of APP from the cell surface (19, 20). Although familial mutations in APP can enhance A secretion (e.g. the Swedish KM  NL mutation; Refs. 20-23), almost all humans express wild type APP. Therefore, the major pathway for A production appears to involve endocytic recycling of APP from the cell surface. To date, the specific contribution of APP endocytic processing to A42 production in particular has not been established.

APP endocytosis relies on signals in the cytoplasmic C-terminal domain. An NPXY sequence similar to that found in the C terminus of the low density lipoprotein receptor (LDLR, 24) and the LDLR-related protein (25) is also found in APP. Because the tyrosine in NPXY is crucial for LDLR endocytosis (24, 26), it has long been assumed that the homologous tyrosine in the APP NPXY motif is the principal signal for APP endocytosis. In the LDLR, an additional amino acid upstream of the NPXY motif was identified as a contributor to LDLR endocytosis, making FXNPXY the accepted LDLR internalization motif (reviewed in Ref. 27). In the only detailed study to date, the APP endocytic signal from an APP-transferrin receptor chimera was localized to the GYENPTY motif (amino acids 737-743), with a potential additional contribution by tyrosine 709 in the YTSI motif adjacent to the membrane (28). However, because the APP-transferrin receptor chimera changed both the orientation and the distance of the potential APP endocytic signal with regard to the plasma membrane, it is uncertain whether this reorientation may have contributed to some of the unexpected findings in that study. In addition, the effect of the endocytic signal on A42 release, in particular, has not been investigated. We therefore undertook extensive mutagenesis studies to identify the specific amino acids required for APP endocytosis and to measure their potential effects on APP processing.

Because tyrosines are associated with endocytosis of multiple proteins (29, 30), we generated point mutations of all the APP cytoplasmic domain tyrosines as well as of the amino acids G, N, and P in the GYENPTY motif. We studied the effects of these mutations in stably transfected cell lines and now report that single amino acids contribute substantially to both APP endocytosis and the release of APP secreted fragments. Of particular note, we observed that although Tyr⁷³⁸, the first tyrosine in GYENPTY, contributed to APP endocytosis, neither the second tyrosine in this motif (Tyr⁷⁴³) nor Tyr⁷⁰⁹ near the membrane were functional endocytic signals. Nonetheless, Y743A mutant cell lines exhibited slower APP turnover. Moreover, we documented a very tight correlation between the degree of APP endocytosis and A secretion. Interestingly, changes in A42 and total A secretion generally paralleled each other, suggesting that endocytic processing contributed to the secretion of both the pathogenic A42 peptide and the more abundantly produced A40 peptide by our cell lines.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Cell Lines-- Chinese hamster ovary (CHO) cells were grown in Dulbecco's modified Eagle's medium (Mediatech/CellGro, Herndon, VA) containing 10% fetal calf serum (HyClone, Logan, UT). Stably transfected CHO cells, selected by G418 (Life Technologies, Inc.) resistance, were maintained in 200 µg/ml G418. The cell lines expressing wild type APP751 (WT) or APP751 with almost the entire cytoplasmic domain deleted (C) have been described (19, 20, 31, 32). CMVAPP695 cDNAs with Y653A and Y682A mutations, kindly provided by Dr. Christian Haass (33), were subcloned into APP751 to produce the Y709A and Y738A mutations. Alanine substitutions at Tyr⁷⁰⁹, Gly⁷³⁷, Tyr⁷³⁸, Asn⁷⁴⁰, Pro⁷⁴¹, and Tyr⁷⁴³ were performed by polymerase chain reaction, confirmed by sequencing, and expressed in CHO cells using pcDNA3 (Invitrogen, Carlsbad, CA) or pCI-neo (Promega, Madison, WI) vectors. Stably transfected CHO cell lines were selected for comparable biosynthetic rates of APP proteins as determined by metabolic labeling and immunoprecipitation using APP ectodomain antibodies (19, 20) to immunoprecipitate full-length APP as described below. A schematic representation of the APP C terminus and the mutated amino acids is illustrated in Fig. 1.

View larger version (30K): [in this window] [in a new window]   Fig. 1.   Schematic diagram of the APP751 C terminus and mutations. The inner aspect of the plasma membrane is represented by the shaded vertical rectangle on the left. APP cytoplasmic domains are represented by horizontal rectangles projecting from the plasma membrane with the APP amino acid sequence indicated using the single-letter code. The top rectangle shows the truncated C terminus of the APP C mutant with its 4-amino acid C-terminal tail, KKKQ. The bottom rectangle represents the native 47-amino acid APP C terminus with the mutated amino acids indicated by arrows and labeled using APP751 numbering with corresponding APP695 numbers in parentheses. YENP, the dominant APP endocytic signal identified in these studies is underlined.

Metabolic Labeling and Antibodies Used-- Nearly confluent cultures of APP transfected CHO cells were incubated in methionine-free Dulbecco's modified Eagle's medium supplemented with 50 µCi/ml [³⁵S]methionine (NEN Life Science Products) for 16 h. Media were collected, cells were lysed using 1% Nonidet P-40 buffer supplemented with protease inhibitors, and APP proteins were immunoprecipitated with APP-specific antibodies (R1282 for total A and monoclonal ectodomain antibodies 5A3 and 1G7 to measure full-length APP and all species of secreted APP_s, as described previously) (19, 20). In three independent experiments, cultures were pulse labeled for 15 min with 150 µCi/ml [³⁵S]methionine and either not chased (for time 0) or chased for 1, 2, or 4 h for measuring the half-life of full-length APP. For these studies, APP was immunoprecipitated with the APP ectodomain antiserum, 863 (34). Half-life was calculated by taking the phosphorimage signal at 1, 2, and 4 h divided by the signal at time 0, thus normalizing the data for cellular expression for each cell line analyzed. Proteins were separated by SDS-polyacrylamide gel electrophoresis (using 6-10% Tris-glycine gels for higher molecular weight proteins and 16.5% Tris-Tricine gels for lower molecular weight proteins). Dried gels were exposed using Transcreen LE with BioMax AR film (Kodak, Rochester, NY) and/or a phosphor screen (Molecular Dynamics, Sunnyvale, CA) for visualizing and quantitating APP proteins. Secreted APP_s and A were measured in 3-8 experiments, and data were normalized to full-length APP expression for each cell line.

Uptake Assay-- Triplicate cultures of CHO cells were grown in 12-well tissue culture plates. To measure internalization of cell surface APP, whole 1G7 monoclonal antibody (to the APP ectodomain) was iodinated as described previously to a specific activity of ~3-6 µCi/µg (10), added to binding medium (RPMI 1640 supplemented with 20 mM Hepes + 0.2% bovine serum albumin) and applied to confluent layers of CHO cells and incubated at 37 °C for 30 min. After incubation, cells were rapidly chilled on ice, and the reaction was quenched by the addition of ice-cold binding medium. After 10 min, chilled cells were washed multiple times with ice-cold Dulbecco's phosphate-buffered saline (Life Technologies, Inc.) to eliminate unbound antibody. Residual antibody bound to surface APP (designated the acid-labile fraction) was then detached from cell surfaces by two 5-min washes with ice-cold phosphate-buffered saline, pH 2.5, and collected into sample tubes. Cells lysed in 0.2 M NaOH (yielding the acid-resistant fraction) were collected into sample tubes. Acid-labile and acid-resistant APP antibody counts were measured by  counting. In control experiments, the acid wash consistently detached 90-95% of cell surface antibody radioactivity from cells that had not been allowed to undergo endocytosis. The ratio of acid-resistant to acid-labile counts provided a measure of the internalized versus cell surface pools of APP. Specific binding was calculated after subtraction of the radioactive counts obtained from parallel cultures of untransfected CHO cells that have minimal amounts of APP on the cell surface.

ELISA-- A sandwich ELISAs were performed as described previously (35, 36). Briefly, capture antibody 266 (to A 13-28) was used for total A, and antibody 21F12 (to A residues 33-42) was used for A42. The reporter antibody for both assays was 3D6 (to A residues 1-5). All experiments were repeated 2-3 times on triplicate samples for each cell line.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Specific Amino Acids in the APP C Terminus Contribute to Endocytosis of Full-length APP-- To assess APP endocytosis in control and mutant stable cell lines we used a well established protocol (10) in which iodinated 1G7 antibody to the APP ectodomain was applied to cultured cells, followed by incubation at 37 °C to monitor the internalization of APP. The APP WT control cell line has been extensively characterized, and APP has been confirmed to undergo rapid internalization, as well as secretion, in this line (10). As expected, WT cells exhibited robust uptake of the specifically surface-bound APP antibody at 37 °C (Fig. 2). APP internalization, indistinguishable from that of WT cells, was observed for cells expressing Y709A, G737A, and Y743A mutations (Fig. 2), indicating that endocytosis of APP was unchanged for these mutant cell lines. In contrast, cells expressing Y738A, N740A, and P741A mutations or the double mutation Y738A/P741A showed dramatically reduced APP internalization (Fig. 2; ANOVA, p < 0.001). The degree of reduction in APP internalization for these four mutant cell lines was comparable with that observed for the cytoplasmic deletion line C (Fig. 2), which has been shown previously to be internalization-deficient (31). These results suggest that the amino acids, Y, N, and P in the YXNP motif (amino acids 738-741) confer the principal ability for APP to undergo rapid endocytosis.

View larger version (45K): [in this window] [in a new window]   Fig. 2.   Endocytosis of full-length APP is markedly diminished in cells expressing Y738A, N740A, P741A, Y738A/P741A, or the C mutation. Uptake of iodinated 1G7 antibody bound to cell surface APP was nearly identical for WT cells and for cells expressing Y709A, G737A, and Y743A mutations. In contrast, cells expressing Y738A, N740A, P741A, Y738A/P741A, or the large APP cytoplasmic deletion (C) had a significantly reduced ratio of internal to surface APP. All data are the means (± S.E.) of four to nine independent experiments, each performed in triplicate and adjusted to the level of full-length APP expression for each cell line. *, p < 0.001.

Cell Lines That Do Not Efficiently Internalize APP from the Cell Surface Secrete More APP_s-- To determine whether diminished APP uptake also may have affected APP proteolytic processing, we next measured the secretion of the total pool of APP_s, the major N-terminal ectodomain fragments released from both control and mutant cell lines after cleavage by - or -secretase. Equivalent normal levels of total APPs were released into the medium of metabolically labeled WT cells and cells expressing APP with point mutations of Y709A, G737A, and Y743A (Fig. 3) entirely consistent with the endocytosis results (Fig. 2). As expected, significantly more total APP_s was secreted by cell lines with diminished APP uptake, i.e. C cells and the cells expressing point mutations Y738A, N740A, P741A, and Y738A/P741A (Fig. 3, ANOVA, p < 0.001).

View larger version (43K): [in this window] [in a new window]   Fig. 3.   Release of APPs is increased by cells expressing Y738A, N740A, P741A, Y738A/P741A, or the C APP C-terminal deletion. Total APPs was immunoprecipitated from the conditioned media of nearly confluent cells labeled 16 h with [35S]methionine, using the APP ectodomain antibodies 1G7 and 5A3 (19, 20), which recognize all APPs species. APPs was separated using SDS-polyacrylamide gel electrophoresis and quantified by phosphorimage analysis. The data are the means (± S.E.) from three independent experiments and adjusted to the level of full-length APP expression for each cell line. *, significance at p < 0.01 or better.

Taken together the data in Figs. 2 and 3 indicate that when APP endocytosis is normal, APP_s secretion is unchanged. Interestingly, both uptake and APPs secretion were normal for cells with tyrosine mutations in the YTSI and NPXY motifs. Although neither Tyr⁷⁰⁹ in YTSI nor Tyr⁷⁴³ in NPXY contributed significantly to APP endocytosis and APP_s secretion, we further analyzed these cell lines to determine whether other aspects of APP processing may have been altered by these mutations.

Mutation of the NPXY Tyrosine but Not the YTSI Tyrosine Affects Full-length APP Turnover-- Full-length APP turnover was measured by pulse chase analysis for WT cells and cells expressing point mutations in the three C-terminal tyrosines, Y709A, Y738A, and Y743A, as well as for the C mutant. No difference in APP turnover was observed for Y738A (Fig. 4), and Y709A or C cell lines (not shown) as compared with WT cells. In contrast, Y743A cells appeared to metabolize APP differently. By pulse chase analysis, Y743A cells showed a significant ~50% increase in half-life as compared with WT and Y738A cells (Fig. 4A; WT = 64 min ± 7.2, Y738A = 56 min ± 7.8, Y743A = 86 min ± 5.0; ANOVA, p < 0.02, data are the averages of three independent experiments). Because half-life is calculated based on the time 0 signal for each cell line, all data are normalized for APP expression and thus unaffected by variations observed in individual experiments.

View larger version (52K): [in this window] [in a new window]   Fig. 4.   Mutation of the Tyr743 in the NPXY motif significantly alters turnover of full-length APP751. In this representative experiment, full-length APP was immunoprecipitated from cell lysates of WT, Y738A, and Y743A cells pulse-labeled with [35S]methionine for 15 min and chased for 0, 1, 2, and 4 h from a representative experiment (A). At time 0, all APP consisted of the immature N-glycosylated species. Both N-glycosylated (immature) and N- and O-glycosylated (mature) species are abundant at 1 h for all three cell lines. More full-length APP is present at 1 and 2 h for Y743A cells compared with both WT and Y738A cells. Most full-length APP has been metabolized by 4 h for all cell lines (A). The ratio of mature to immature APP reveals a significant increase for Y743A cells compared with WT or Y738A cells at 1 h and 2 h (B). Half-life was calculated by taking the phosphorimage signal at 1, 2, and 4 h divided by the signal at time 0, thus normalizing the data for each cell line. The data are the averages (± S.E.) from three independent experiments. *, significance at p < 0.001.

Moreover, when we compared the levels of mature and immature APP for these same three cell lines, Y743A cells had a significantly greater ratio of mature to immature full-length APP at both 1 h and 2 h than either WT or Y738A cells (Fig. 4B, p < 0.001). These data indicate that both mature and immature full-length APP were retained at later time points by cells expressing the Y743A mutation compared with WT or Y738A cells. Therefore, although Tyr⁷⁴³ does not appear to be an endocytic signal, this APP tyrosine contributes to normal APP turnover.

Total A Secretion Is Dramatically Reduced by Cells Expressing C, Y738A, N740A, P741A or, Y738A/P741A Mutations-- To determine whether other aspects of APP processing were affected by the C-terminal mutations, we next measured the metabolic production and release of A from our WT and mutant stable CHO cell lines. Total A secretion was measured using antibody R1282 to immunoprecipitate all A species from conditioned medium of cells labeled overnight with [³⁵S]methionine. WT cells and cells expressing Y709A, G737A, and Y743A mutations secreted equivalent amounts of total A consistent with their ability to internalize full-length APP (Fig. 5). In contrast, cells expressing mutants deficient in endocytosis, i.e. the C-terminal deletion C or point mutations Y738A, N740A, P741A, or Y738A/P741A all had significantly reduced levels of total A released from the cells into the medium (Fig. 5; ANOVA, p < 0.0001). These results confirm that mutations that reduced APP internalization also reduced the levels of total A secreted by the cells. Because the antibody used to immunoprecipitate A in these studies recognizes all A species (i.e. mostly A40 peptides) we were unsure whether defective endocytosis affected A42 release as well. Therefore, we next evaluated the levels of A42 in medium from the WT and mutant cell lines.

View larger version (53K): [in this window] [in a new window]   Fig. 5.   Secretion of total A is reduced by cells expressing Y738A, N740A, P741A, Y738A/P741A, or a large APP C-terminal deletion, C. A immunoprecipitated by R1282 from conditioned medium of cells labeled 16 h with [35S]methionine was separated by 16.5% Tris-Tricine SDS-polyacrylamide gel electrophoresis prior to phosphorimage analysis. WT cells and cells expressing Y709A, G737A, and Y743A mutations produce normal levels of A consistent with their ability to internalize full-length APP. In contrast, cells expressing Y738A, N740A, P741A, Y738A/P741A, or a large APP C-terminal deletion, C, have significantly reduced levels of total A secretion (A), as seen in a representative autoradiogram (B). The A levels in B, although not normalized for APP expression, were obtained from cells expressing comparable levels of APP. Data in A are the means (± S.E.) from 4-8 independent experiments, normalized for full-length APP expression. *, significance at p < 0.01 or better.

A42 Secretion Is Dramatically Reduced by Mutations That Diminish APP Endocytosis-- We measured both total A (principally A40) and A42 levels in media conditioned for 24 h by WT cells and by cells expressing the various C-terminal mutations using a well characterized and sensitive sandwich ELISA (35, 36). In striking parallel to their abilities to efficiently internalize APP, WT cell lines and the Y709A, G737A, and Y743A mutant cell lines released similar levels of total A and A42, suggesting that A release was normal for these cell lines. Not surprisingly, the ratios of A42 to total A in medium were unchanged in these three mutant cell lines (Fig. 6). In sharp contrast, cells expressing mutations that diminished APP endocytosis showed significantly reduced A42 secretion. The C-terminal deletion, C, and point mutations of Y738A, N740A, P741A, and Y738A/P741A of GYENPTY all resulted in significantly less A42 secretion relative to total A than that observed for the WT, Y709A, G737A, and Y743A cell lines (Fig. 6) revealing for the first time that mutations that diminish APP internalization dramatically reduce A42 secretion. These data suggest that recycling of full-length APP contributes significantly to the pool of both A40 and A42 produced and released from cells during normal metabolic processing.

View larger version (52K): [in this window] [in a new window]   Fig. 6.   A42 secretion is selectively decreased by mutations that reduce APP uptake. Conditioned media of WT and various C-terminal mutant cell lines were assayed by a sensitive sandwich ELISA to measure the levels of total A and A42 secreted into the conditioned medium in 24 h. WT cells and cells expressing Y709A, G737A, and Y743A mutations produce similar levels of A42, whereas cells expressing Y738A, N740A, P741A, Y738A/P741A, or a large APP C-terminal deletion, C, have significantly reduced levels of total A42 secretion. Data are the means (± S.E.) from three independent experiments on triplicate samples for each cell line. *, significance at p < 0.01 or better.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Stably transfected CHO cells have been shown in numerous studies to process APP similarly to other cells (e.g. Refs. 7 and 37-39) and thus provide a good model for studying APP trafficking and metabolism (6, 10, 19, 20, 28, 31). Analyses of our stably transfected CHO cells expressing WT APP or APP with various C-terminal mutations have generated three major and novel findings regarding APP trafficking and processing. First, we have identified the tetrapeptide motif, YXNP (amino acids 738-741 in APP751 or 682-685 in APP695) in the APP C terminus as the dominant APP endocytic signal. Second, we observed that whereas mutation of Tyr⁷⁴³ in the NPXY motif had no effect on APP endocytosis, this mutation significantly altered metabolism (half-life) of full-length APP. Third, we identified dramatic and parallel effects on the secretion of APP_s, total A, and A42 in association with C-terminal mutations that altered normal APP endocytosis.

Some APP holoprotein, including cell surface APP, is found in clathrin-coated vesicles (5, 6), indicating that APP utilizes a clathrin-based endocytic pathway. Many integral membrane proteins, including APP, undergo continued recycling and trafficking throughout their lifetime, a phenomenon common to cell surface receptors (extensively reviewed in Ref. 27). A key receptor molecule used to define endocytic recycling is the LDLR (e.g. 24, 26, 27). Based on its role in LDLR endocytosis, NPXY has been assumed to be the signal for APP endocytosis (24). In addition to the four amino acids of this NPXY motif, an aromatic amino acid residue upstream of NPXY also contributes to LDLR endocytosis, making the recognized endocytic signal for this molecule the hexapeptide motif FXNPXY (24). Once FXNPXY had been defined as the LDLR endocytic motif, an analogous sequence in the APP C terminus, YENPTY, became the primary focus for APP endocytosis and trafficking studies (19, 28, 31, 33, 37). Although studies suggested that the APP endocytic signal was localized within this YXNPXY motif, the specific amino acids underlying APP endocytosis remained undefined. Furthermore, potential contributions to endocytosis had also been suggested for the proximal tyrosine Tyr⁷⁰⁹ (in the YTSI motif), and for the glycine (Gly⁷³⁷) in GYENPTY of APP (28). Therefore, we systematically analyzed the residues thought to contribute to APP endocytosis using a well characterized method for evaluating APP endocytosis (10).

In our study, we show that mutations of Tyr, Asn, or Pro or a double mutation of Tyr and Pro but not a mutation of the C-terminal Tyr in YENPTY significantly diminish APP endocytosis. Point mutations within the YXNP motif all reduced APP internalization dramatically. Therefore, our data strongly suggest that the four amino acid sequence, YENP, is the major signal for clathrin-mediated APP endocytosis. The single amino acid Asn⁷⁴⁰ appears to be a major component of the APP endocytic signal because the N740A mutation alone reduced endocytosis to a level similar to that observed for cells (C) lacking nearly the entire APP cytoplasmic domain.

In addition, our data showed that neither Tyr⁷⁰⁹ nor Gly⁷³⁷ contributed to APP internalization in our studies, suggesting that these amino acids, like Tyr⁷⁴³ in NPXY, are not part of the APP endocytic signal. In native APP, Tyr⁷⁰⁹ lies 5 amino acids from the plasma membrane, rather than 46 amino acids from the plasma membrane as was the case in the reported APP-transferrin-receptor chimera (28), and this may explain why the YTSI tyrosine promoted internalization in the latter model. Although N-terminal ectodomain residues of APP may play a role in basolateral sorting in polarized epithelial cells (37), support for the YTSI tyrosine subserving basolateral sorting of APP has also been shown (33). It may be that the YTSI tyrosine (Tyr⁷⁰⁹ in APP751 and Tyr⁶⁵³ in APP695) interacts with the newly identified PAT1 molecule (a protein with kinesin homology that interacts with microtubules) to sort APP to the basolateral compartment in polarized epithelial cells (40).

Regarding the role of Tyr⁷⁴³ in APP processing we found that Tyr⁷⁴³ in the NPXY motif is not an APP endocytic signal and that cells overexpressing APP with this mutation produced normal levels of A. Although endocytosis was not measured in their studies, other investigators using cells with mutations of the NPXY tyrosine have also observed normal A secretion from their cell lines (41, 42). Although therefore not an endocytic signal, Tyr⁷⁴³, when mutated, reduced the otherwise rapid turnover of APP. Although the APP half-life was longer in Y743A cells, APP was converted from immature to fully glycosylated APP similarly to WT and Y738A APP, suggesting that trafficking through the Golgi compartment was normal for these cell lines. Thus, we speculate that Tyr⁷⁴³ may function, in part, as a lysosomal targeting signal for APP.

We previously showed that cells expressing C-terminal deletions have reduced levels of total A secretion (19, 31). As anticipated, total A release was again diminished by cells expressing mutations that reduced APP endocytosis. Specifically, Y738A, N740A, P741A, Y738A/P741A, and C cell lines all had dramatically reduced total A secretion as measured by immunoprecipitation. No decrease in total A secretion was observed for Y709A, G737A, or Y743A, cell lines that also had normal APP endocytosis. These data strongly reinforce the importance of the endocytic pathway for the generation of total A released by cells.

When we measured A42 secretion by sandwich ELISA we were surprised to see that in parallel with the diminution of total A secretion, the Y738A, N740A, P741A, Y738A/P741A, and C cell lines also secreted less A42. This unexpected finding suggested that processing of APP in the endocytic pathway contributes substantially to A42 secretion. However, non-neuronal (20, 42-45) and neuronal cells (46-48) are known to produce and, under some conditions, accumulate intracellular A. Because several studies have identified A42 production in the early compartments of the secretory processing pathway (42, 45, 47-50), we were surprised to see that endocytic processing appeared to contribute significantly to the pool of A42 secreted from our mutant cell lines. However, it is not known whether the intracellular A identified in the earlier studies ultimately gets secreted by the cells. Our results suggest that perhaps most A42 does not become secreted, because the level of A42 released into the medium was strongly dependent on the endocytic signal. Because we did not measure intracellular A species in our current studies, measurements for total A, A40, and A42 in cell lysates or in isolated endoplasmic reticulum or Golgi vesicles of our C-terminal mutants will be required to determine whether or not a deficiency in endocytosis can affect the various intracellular A species. Furthermore, it should be noted that although our data indicate that mutations that affected APP internalization reduced A secretion, whether the same mutations may have affected exocytic APP trafficking remains to be elucidated.

Although it is unknown how the amino acids in the YXNP motif mediate endocytosis, it is appealing to speculate that it may occur by interaction with APP-binding proteins such as BP1, X11, or Fe65 (reviewed in Ref. 51). Recent data in which APP processing was assessed in cells overexpressing X11 or Fe65 (52, 53) suggest that the interaction of APP with these molecules may occur in different pathways and that A production is perturbed by altered protein-protein interactions of this sort. X11 may bind to APP primarily in the secretory pathway because overexpression of X11 reduced APP_s cleaved by -secretase (52), possibly because of reduced amounts of APP arriving at the cell surface. Conversely, interaction with Fe65 may occur in an early stage of the endocytic pathway because overexpression of human Fe65 (hFe65L) in H4 neuroglioma cells increased APP_s secretion (53), an effect possibly related to retention of APP at or near the cell surface, where it could undergo enhanced -secretase cleavage, as recently reported for MDCK cells overexpressing rat Fe65 (54). This enhancement of -secretase cleavage may be associated with APP binding to caveolin-1 within plasma membrane microdomains (55). Additionally, an NPXY motif-dependent interaction between APP and the receptor LDLR-related protein by way of the cytosolic adaptor proteins mDab (mammalian Disabled protein) and Fe65 has also been identified that may affect APP trafficking and processing (56). These possibilities require additional experimental validation.

In conclusion, our data indicate that the dominant signal for APP endocytosis resides in the motif YXNP, that other signals in the APP C terminus contribute to different APP processing/trafficking pathways, and that endocytic trafficking of APP contributes importantly to both APP_s and A secretion. Further understanding of the mechanisms by which cells convert APP into secreted fragments may provide new insights for designing or testing the efficacy of inhibitors of A generation and secretion as potential treatments for AD.

	ACKNOWLEDGEMENTS

We thank Dr. Christian Haass for CMVAPP695 cDNAs and Dr. Peter Seubert (Elan Pharmaceuticals Inc., South San Francisco, CA) for ELISA antibodies 266, 21F12, and 3D6.

	FOOTNOTES

^* This work was supported by grants from the Nathan Shock Center for Excellence and by Allegheny University of the Health Sciences Grant 98-017-3P (to R. G. P.), and National Institutes of Health Grants AG06173 (to D. J. S.) and AG12376 and NS01812 (to E. H. K.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ To whom correspondence should be addressed: 125 George St., Turtle Creek, PA 15145-1014; E-mail: perez{at}pitt.edu

	ABBREVIATIONS

The abbreviations used are: APP, -amyloid precursor protein; AD, Alzheimer's disease; LDLR, low density lipoprotein receptor; CHO, Chinese hamster ovary; WT, wild type; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; ELISA, enzyme-linked immunosorbent assay; ANOVA, analysis of variance. APP_s, secreted N₁-terminal ectodomain of APP.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

1. Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., and Muller-Hill, B. (1987) Nature 325, 733-736[CrossRef][Medline] [Order article via Infotrieve]
2. Shivers, B. D., Hilbich, C., Multhaup, G., Salbaum, M., Beyreuther, K., and Seeburg, P. H. (1988) EMBO J. 7, 1365-1370[Medline] [Order article via Infotrieve]
3. Breen, K., Bruce, M., and Anderson, B. (1991) J. Neurosci. Res. 28, 90-100[CrossRef][Medline] [Order article via Infotrieve]
4. Jung, S. S., Nalbantoglu, J., and Cashman, N. R. (1996) J Neurosci. Res. 46, 336-348[CrossRef][Medline] [Order article via Infotrieve]
5. Nordstedt, C., Caporaso, G. L., Thyberg, J., Gandy, S. E., and Greengard, P. (1993) J. Biol. Chem. 268, 608-612[Abstract/Free Full Text]
6. Yamazaki, T., Koo, E. H., and Selkoe, D. J. (1996) J. Cell Sci. 109, 999-1008[Abstract]
7. Haass, C., Koo, E. H., Mellon, A., Hung, A. Y., and Selkoe, D. J. (1992) Nature 357, 500-503[CrossRef][Medline] [Order article via Infotrieve]
8. Golde, T., Estus, S., Younkin, L., Selkoe, D., and Younkin, S. (1992) Science 255, 728-730[Abstract/Free Full Text]
9. Yamazaki, T., Selkoe, D. J., and Koo, E. H. (1995) J. Cell Biol. 129, 431-442[Abstract/Free Full Text]
10. Koo, E. H., Squazzo, S. L., Selkoe, D. J., and Koo, C. H. (1996) J. Cell Sci. 109, 991-998[Abstract]
11. Selkoe, D. J. (1994) Curr. Opin. Neurobiol. 4, 708-716[CrossRef][Medline] [Order article via Infotrieve]
12. Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., and Selkoe, D. J. (1992) Nature 359, 322-325[CrossRef][Medline] [Order article via Infotrieve]
13. Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., and Younkin, S. G. (1992) Science 258, 126-129[Abstract/Free Full Text]
14. Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Vitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., and Younkin, S. (1996) Nat. Med. 2, 864-870[CrossRef][Medline] [Order article via Infotrieve]
15. Jarrett, J. T., Berger, E. P., and Lansbury, P. T., Jr. (1993) Ann. N. Y. Acad. Sci. 695, 144-148[Abstract]
16. Selkoe, D. J. (1996) Cold Spring Harbor Symp. Quant. Biol. 56, 587-596
17. Mann, D. M., Iwatsubo, T., Cairns, N. J., Lantos, P. L., Nochlin, D., Sumi, S. M., Bird, T. D., Poorkaj, P., Hardy, J., Hutton, M., Prihar, G., Crook, R., Rossor, M. N., and Haltia, M. (1996) Ann. Neurol. 40, 149-156[CrossRef][Medline] [Order article via Infotrieve]
18. Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., and Selkoe, D. J. (1996) Neurobiol. Dis. 3, 16-32[CrossRef][Medline] [Order article via Infotrieve]
19. Koo, E. H., and Squazzo, S. L. (1994) J. Biol. Chem. 269, 17386-17389[Abstract/Free Full Text]
20. Perez, R. G., Squazzo, S. L., and Koo, E. H. (1996) J. Biol. Chem. 271, 9100-9107[Abstract/Free Full Text]
21. Citron, M., Oltersdorf, T., Haass, C., McConologue, K., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., and Selkoe, D. J. (1992) Nature 360, 672-674[CrossRef][Medline] [Order article via Infotrieve]
22. Cai, X.-D., Golde, T. E., and Younkin, S. G. (1993) Science 259, 514-516[Abstract/Free Full Text]
23. Felsenstein, K. M., Hunihan, L. W., and Roberts, S. B. (1994) Nat. Gen. 6, 251-256[CrossRef][Medline] [Order article via Infotrieve]
24. Chen, W.-J., Goldstein, J. L., and Brown, M. S. (1990) J. Biol. Chem. 265, 3116-3123[Abstract/Free Full Text]
25. Herz, J., Hamann, U., Rogne, S., Myklebost, O., Gausepohl, H., and Stanley, K. K. (1988) EMBO J. 7, 4119-4127[Medline] [Order article via Infotrieve]
26. Davis, C. G., Lehrman, M. A., Russell, D. W., Anderson, R. G., Brown, M. S., and Goldstein, J. L. (1986) Cell 45, 15-24[CrossRef][Medline] [Order article via Infotrieve]
27. Trowbridge, I. S., Collawn, J. F., and Hopkins, C. R. (1993) Annu. Rev. Cell Biol. 9, 129-161[CrossRef]
28. Lai, A., Sisodia, S., and Trowbridge, I. (1995) J. Biol. Chem. 270, 3565-3573[Abstract/Free Full Text]
29. Ohno, H., Stewart, J., Fournier, M. C., Bosshart, H., Rhee, I., Miyatake, S., Saito, T., Gallusser, A., Kirchhausen, T., and Bonifacino, J. S. (1995) Science 269, 1872-1875[Abstract/Free Full Text]
30. Leitinger, B., Hille-Rehfeld, A., and Spiess, M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10109-10113[Abstract/Free Full Text]
31. Perez, R. G., and Koo, E. H. (1997) in Alzheimer's Disease: Biology, Diagnosis and Therapeutics (Iqbal, K. , Winblad, B. , Nishimura, T. , Takeda, M. , and Wisniewski, H., eds) , pp. 407-416, John Wiley and Sons, Ltd., London
32. Xia, W.-M., Zhang, J., Perez, R. G., Koo, E. H., and Selkoe, D. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 8208-8213[Abstract/Free Full Text]
33. Haass, C., Koo, E. H., Capell, A., Teplow, D. B., and Selkoe, D. J. (1995) J. Cell Biol. 128, 537-547[Abstract/Free Full Text]
34. Marquez-Sterling, N., Lo, A. C. Y., Sisodia, S., and Koo, E. H. (1997) J. Neurosci. 17, 140-151[Abstract/Free Full Text]
35. Johnson-Wood, K., Lee, M., Motter, R., Hu, K., Gordon, G., Barbour, R., Khan, K., Gordon, M., Tan, H., Games, D., Lieberburg, I., Schenk, D., Seubert, P., and McConlogue, L. (1997) Proc. Nat. Acad. Sci. U. S. A. 94, 1550-1555[Abstract/Free Full Text]
36. Xia, W., Zhang, J., Kholodenko, D., Citron, M., Podlisny, M. B., Teplow, D. B., Haass, C., Seubert, P., Koo, E. H., and Selkoe, D. J. (1997) J. Biol. Chem. 272, 7977-7982[Abstract/Free Full Text]
37. De Strooper, B., Craessaerts, K., Dewachter, I., Moechars, D., Greenberg, B., Van Leuven, F., and Van Den Berghe, H. (1995) J. Biol. Chem. 270, 4058-4065[Abstract/Free Full Text]
38. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I., and Schenk, D. (1992) Nature 359, 325-327[CrossRef][Medline] [Order article via Infotrieve]
39. Citron, M., Vigo-Pelfrey, C., Teplow, D. B., Miller, C., Schenk, D., Johnston, J., Winblad, B., Venizelos, N., Lannfelt, L., and Selkoe, D. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11993-11997[Abstract/Free Full Text]
40. Zheng, P., Eastman, J., Vande Pol, S., and Pimplikar, S. W. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 14745-14750[Abstract/Free Full Text]
41. Jacobsen, J. S., Spruyt, M. A., Brown, A. M., Sahasrabudhe, S. R., Blume, A. J., Vitek, M. P., Muenkel, H., A., and Sonnenberg-Reines, J. (1994) J. Biol. Chem. 269, 8376-8382[Abstract/Free Full Text]
42. Wild-Bode, C., Yamazaki, T., Capell, A., Leimer, U., Steiner, H., Ihara, Y., and Haass, C. (1997) J. Biol. Chem. 272, 16085-16088[Abstract/Free Full Text]
43. Knauer, M. F., Soreghan, B., Burdick, D., Kosmoski, J., and Glabe, C. G. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7437-7441[Abstract/Free Full Text]
44. Martin, B. L., Schrader-Fischer, G., Busciglio, J., Duke, M., Paganetti, P., and Yankner, B. A. (1995) J. Biol. Chem. 270, 26727-26730[Abstract/Free Full Text]
45. Xia, W., Zhang, J., Ostaszewski, B. L., Kimberly, W. T., Seubert, P., Koo, E. H., Shen, J., and Selkoe, D. J. (1998) Biochemistry 37, 16465-16471[CrossRef][Medline] [Order article via Infotrieve]
46. Turner, R. S., Suzuki, N., Chyung, A. S. C., Younkin, S. G., and Lee, V. M.-Y. (1996) J. Biol. Chem. 271, 8966-8970[Abstract/Free Full Text]
47. Chyung, A. S. C., Greenberg, B. D., Cook, D. G., Doms, R. W., and Lee, V. M. (1997) J. Cell Biol. 138, 671-680[Abstract/Free Full Text]
48. Cook, D. G., Forman, M. S., Sung, J. C., Leight, S., Kolson, D. L., Iwatsubo, T., Lee, V. M., and Doms, R. W. (1997) Nat. Med. 3, 1021-1023[CrossRef][Medline] [Order article via Infotrieve]
49. Tienari, P. J., Ida, N., Ikonen, E., Simons, M., Weidemann, A., Multhaup, G., Masters, C. L., Dotti, C. G., and Beyreuther, K. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4125-4130[Abstract/Free Full Text]
50. Hartmann, T., Bieger, S. C., Bruhl, B., Tienari, P. J., Ida, N., Allsop, D., Roberts, G. W., Masters, C. L., Dotti, C. G., Unsicker, K., and Beyreuther, K. (1997) Nat. Med. 3, 1016-1020[CrossRef][Medline] [Order article via Infotrieve]
51. Russo, T., Faraonio, R., Minopoli, G., DeCandia, P., De Renzis, S., and Zambrano, N. (1998) FEBS Lett. 434, 1-7[CrossRef][Medline] [Order article via Infotrieve]
52. Borg, J. P., Yang, Y., De Taddeo-Borg, M., Margolis, B., and Turner, R. S. (1998) J. Biol. Chem 273, 14761-14766[Abstract/Free Full Text]
53. Guenette, S., Chen, J., Ferland, A., and Tanzi, R. (1998) Neurobiol. Aging 19, S72
54. Sabo, S. L., Lanier, L. M., Ikin, A. F., Khorkova, O., Sahasrabudhe, S., Greengard, P., and Buxbaum, J. D. (1999) J. Biol. Chem. 274, 7952-7957[Abstract/Free Full Text]
55. Ikezu, T., Trapp, B. D., Song, K. S., Schlegel, A., Lisanti, M. P., and Okamoto, T. (1998) J. Biol. Chem. 273, 10485-10495[Abstract/Free Full Text]
56. Trommsdorff, M., Borg, J.-P., Margolis, B., and Herz, J. (1998) J. Biol. Chem. 273, 33556-33560[Abstract/Free Full Text]